Hygrovest Limited Overview
Underwood Capital Limited is a Sydney-based, ASX-listed specialist investment company that has spent the last decade evolving from a vertically integrated medical-cannabis venture (Phytotech Medical, 2015) into a diversified, value-oriented small-cap investment vehicle. From 2018 to 2023, as MMJ Group Holdings and then Hygrovest, it was Australia's principal listed vehicle for minority investments in North American cannabis companies, an exposure that produced cumulative losses exceeding A$60 million over FY2020–FY2023. Since 1 July 2023 the portfolio has been managed by HD Capital Partners, which has liquidated nearly all legacy cannabis assets and redeployed capital into concentrated positions in cash-generative, ASX-listed business-to-business service and software companies. At 30 June 2026 the company held A$13.5m of listed securities, A$0.7m cash and a A$7.0m stake in Canadian cannabis producer Weed Me Inc., its final legacy asset. The shares trade at roughly a 40–45% discount to post-tax NTA, below the value of its liquid assets alone.
Company's own description
The FY2026 Annual Report describes the principal activity as follows (paraphrased closely to preserve meaning): UWC is an Australian-listed specialist investment company that has traded on the ASX since 2015; investors gain exposure to a portfolio that primarily seeks to produce capital growth over the medium term from investments in listed and unlisted equities and debt securities. Investments are managed by HD Capital Partners under an Investment Management Agreement running from 1 July 2023 to 30 June 2028. The company measures and evaluates substantially all investments on a fair value basis.
The FY2026 Directors' Report adds a stated goal: to significantly outperform global equity markets over rolling five-year periods by taking concentrated, long-term positions in undervalued and overlooked companies while prioritising protection of capital.
Aggregator profiles of the HD Capital mandate (Pearler, based on company disclosures) describe three target categories: undervalued, well-managed growth companies, often founder-led, that are off the radar of the broader investment community; undervalued securities where the company seeks to realise value; and special situations dependent on a corporate action such as mergers, liquidations, tender offers and divestments.
Business model and "revenue" model
| Income component | FY2025 (AUD K) | FY2026 (AUD K) | Nature |
|---|---|---|---|
| Interest and dividend income | 540 | 427 | Recurring cash yield from listed holdings, the AAA cash ETF and (in FY2026) dividends from Weed Me |
| Net unrealised gains/(losses) on financial instruments at FVTPL | 1,529 | (698) | Mark-to-market; non-cash, volatile |
| Realised gains/(losses) on disposal | (1,216) | 955 | Crystallised on sale |
| Other operating income | 83 | 0 | Non-recurring |
| Total income | 936 | 684 | — |
Underwood has no products, services, subscriptions or licensing. Its "revenue" (reported as total income) comprises three components, all arising from the investment portfolio:
Source: UWC FY2026 Annual Report, Statement of Profit or Loss. (The Appendix 4E headline shows FY2025 revenue as 937; the statement shows 936 — a rounding difference.)
Costs comprise investment management fees (1% p.a. of pre-tax NAV, plus a 20% performance fee above a 6% hurdle and high-water mark), employee and director costs, and administration and listing costs. Value creation for shareholders is therefore a function of (a) gross portfolio returns, (b) the cost ratio, (c) tax, and (d) the market's discount to NTA, which the company is attempting to arbitrage through on-market buybacks.
Value chain position, customers and end-markets
As an LIC, Underwood sits at the capital-provider end of the value chain: it supplies permanent equity capital to listed small caps (by buying in the secondary market) and, historically, growth capital to private cannabis companies. Its "customers" are its shareholders — 2,623 holders at 21 July 2026, predominantly retail and self-managed superannuation funds, with the manager's principals and associates among the largest holders. Its end-markets are the companies it owns: at 30 June 2026, ASX-listed B2B services and software (Airtasker, Kip McGrath Education Centres, Cuscal, Fiducian Group, Cogstate, LaserBond, Praemium, ReadyTech, Reckon), a cash ETF (Betashares AAA), and Canadian adult-use cannabis consumer packaged goods (Weed Me Inc.).
Independent characterisation
Underwood is best understood as a sub-scale, closed-end value fund in transition. The strategic story has three acts. Act one (2015–2018) was an operating medical-cannabis company (Phytotech) that pivoted to an investment holding model after Harvest One diluted it out of control. Act two (2018–2023) was a thematic cannabis investment company managed from Canada by Parallax Ventures, which suffered heavily from the 2019–2023 collapse in Canadian cannabis valuations; NTA fell from roughly 20.5c per share in March 2021 to about 9.2c by June 2023, with an unmarketable-parcel buyback and a cost-cutting program following. Act three (July 2023 onward) is a value-investing turnaround under HD Capital Partners: liquidate legacy illiquids, cut costs, buy back stock at a discount, and compound in concentrated ASX small caps.
The key structural problem is scale. With roughly A$19m of net assets and operating costs of A$0.84m in FY2026 (about 4.4% of average net assets), the vehicle needs a gross return of roughly 4–5% just to stand still before tax. The key structural opportunity is the discount: the share price (about 5.4c) sits below the value of cash and listed securities alone (about 6.9c per share pre-tax), so investors are effectively being paid to take the Weed Me stake.
Strategy
Stated strategy (themes from FY2024 and FY2026 Annual Reports)
The board's three-pillar improvement program, first articulated in FY2024 and reaffirmed in FY2026, is:
-
Maximise the value of existing investments — realise legacy cannabis assets "in a rational and patient manner" and only when in shareholders' interests (Proactive summary of October 2024 investment report).
-
Maintain a value-focused investment approach — concentrated, long-term positions in undervalued and overlooked companies, with explicit emphasis on downside protection and "what can go wrong".
-
Minimise fixed costs — the explicit cost program delivered a 46% fall in operating expenses over FY2023–FY2026.
The overarching objective is to significantly outperform global equity markets over rolling five-year periods.
The FY2026 manager letter adds investment-style themes: preference for mission-critical products and services with predictable revenues and strong free cash flow (which skews the portfolio toward technology); a view that, in the short term, AI is more likely to benefit entrenched software businesses through lower costs and faster development, but that the long-run impact is unknowable; and a deliberate focus on "easier games" in market corners others cannot or will not fish in.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Rebrand to Underwood Capital | Dec 2024 | Removes cannabis association ("Hygrovest"); new ticker UWC and website uwcl.com.au | Complete |
| Legacy asset liquidation | Sep–Oct 2024 | ETG sold for A$3.8m; Delivra sold for about C$1.1m | Complete; Weed Me remains |
| Weed Me monetisation | Ongoing | Manager publicly invites approaches from acquirers for the stake (FY2026 letter) | Active |
| On-market buyback #1 | Sep 2024 – Oct 2025 | Up to 21,031,060 shares; capped at 105% of 5-day VWAP | Expired; small volumes executed |
| On-market buyback #2 | From 10 Apr 2026 | Up to about 20,532,686 shares; 1,796,057 bought at an average A$0.0525 by 30 Jun 2026 | Active. TipRanks reports an Appendix 3C update extending a buyback to 27 Oct 2026 — the relationship between this update and the March 2026 program is unclear from available sources |
| Unmarketable-parcel buybacks | Jun 2023; FY2025 | 19.64m shares (A$1.04m) and 4.57m shares (A$0.23m) cancelled; holders with unmarketable parcels fell from 1,311 (Aug 2024) to 535 (Jul 2026) | Complete |
| Corporate simplification | Dec 2025 | UK subsidiary deregistered | Complete |
| Audit cost reduction | Mar 2024; Mar 2026 | Two auditor changes; total audit fees fell from A$114k (FY2023) to A$52k (FY2026) | Complete |
Medium-term targets and guidance
No quantitative financial guidance or medium-term targets are published. The only explicit operating target disclosed was the FY2024 forecast that non-management-fee operating costs would fall from more than A$1.3m (FY2023) to around A$0.7m (FY2025). ESG or sustainability commitments: none disclosed. The company states the performance of its portfolio is materially dependent on overall global equity market performance.
Products & Services
Underwood sells no products or services. The functional equivalent of a product catalogue for an LIC is its investment portfolio, which is what shareholders buy exposure to. The complete disclosed holdings list (ASX Listing Rule 4.10.20) follows.
Holdings at 30 June 2026 (FY2026 Annual Report)
| Holding | Type | Exchange / domicile | Description (analyst characterisation) |
|---|---|---|---|
| Weed Me Inc. | Unlisted equity | Canada | Licensed Canadian cannabis producer focused on convenience-category brands; book value A$6.982m; reported record sales and paid a dividend in 2026 per its CEO |
| Betashares Australian High Interest Cash ETF (AAA) | Listed ETF | ASX | Cash-equivalent liquidity reserve; A$0.388m |
| Airtasker Ltd (ART) | Listed equity | ASX | Online services marketplace |
| Kip McGrath Education Centres Ltd (KME) | Listed equity | ASX | Tutoring franchise network |
| Cuscal Ltd (CCL) | Listed equity | ASX | Payments and banking infrastructure provider |
| Fiducian Group Ltd (FID) | Listed equity | ASX | Financial planning and platform administration |
| Cogstate Ltd (CGS) | Listed equity | ASX | Cognitive assessment technology for clinical trials and healthcare |
| LaserBond Ltd (LBL) | Listed equity | ASX | Surface engineering and wear-protection services |
| Praemium Ltd (PPS) | Listed equity | ASX | Investment platform and portfolio administration software |
| ReadyTech Holdings Ltd (RDY) | Listed equity | ASX | Mission-critical SaaS for education, workforce and government |
| Reckon Ltd (RKN) | Listed equity | ASX | Accounting and practice-management software |
| GM Health Group Pty Ltd | Unlisted equity | Australia | Legacy small unlisted holding; value not separately disclosed (believed immaterial) |
Aggregate listed equities excluding AAA: A$13.104m. Individual position sizes are not publicly disclosed in the annual report. The manager states the listed book consists entirely of ASX-listed B2B service companies purchased at low multiples of normalised free cash flow (FY2026 Investment Manager Report).
Holdings at 30 June 2024 (FY2024 Annual Report) — for comparison
| Holding | Type | Value AUD K (where disclosed) |
|---|---|---|
| Weed Me Inc. (equity) | Unlisted | 9,171 |
| Emerging Therapeutics Group (formerly Southern Cannabis Holdings) | Unlisted | 3,993 |
| Delivra Health Brands (formerly Harvest One) | Listed TSX-V | 2,131 |
| Valo Therapeutics Oy (convertible/loan) | Unlisted, Finland | 600 |
| Sequoya Cannabis (convertible/loan) | Unlisted, Canada | 247 |
| Other listed securities (Ainsworth Game Technology, Airtasker, BevCanna Enterprises, Centrepoint Alliance, Fiducian, Praemium, Reckon, Reklaim, Vintage Wine Estates, AAA ETF) | Listed | 4,647 |
| Other unlisted (Bespoke A LP, Bowery Capital Mortgage & Investment Fund, Eildon Debt Fund, GM Health Group) | Unlisted | 754 |
Investment management "service terms" (the price shareholders pay)
| Term | Detail |
|---|---|
| Manager | HD Capital Partners Pty Ltd (principals who signed the FY2026 manager letter: Daniel Sims and Harley Grosser) |
| Term | 5 years, 1 Jul 2023 – 30 Jun 2028 |
| Base fee | 1.0% p.a. (plus GST) of pre-tax NAV, paid monthly |
| Performance fee | 20% (plus GST) of pre-tax NAV above the high-water mark compounded at a 6% p.a. hurdle, adjusted for capital flows; nil if portfolio value falls |
| Base fees paid | FY2024 A$171,287; FY2026 A$249,287 (FY2025 not separately extracted; asset management expenses A$211k) |
| Performance fees paid | Nil in FY2024, FY2025 and FY2026 |
| Predecessor | Parallax Ventures Inc. (Canada), base fees A$188,608 in FY2023, no performance fee |
Financial Narrative
Income statement (A$000 unless stated)
Sources: FY2024 Annual Report (FY2022–FY2024 five-year table and income statement); FY2026 Annual Report (FY2025–FY2026). "n/d" = not disclosed in the documents obtained.
Longer history for context: FY2020 total income -41,258, NPAT -40,082, EPS -17.61c; FY2021 total income -5,184, NPAT -4,024, EPS -1.75c (FY2024 Annual Report). FY2019 net profit A$21.6m (Barchart; aggregator).
Operating expense detail
Sources: FY2024 and FY2026 Annual Reports.
Margins and growth
Analyst calculations. Margins on total income are of limited interpretive value because "revenue" includes mark-to-market movements; the expense ratio is the more relevant efficiency metric. NPAT exceeds PBT in FY2025 and FY2026 because of tax benefits from deferred-tax reversals and reconciling items.
Balance sheet (A$000 at 30 June)
Sources and derivations: FY2023–FY2024 from FY2024 Annual Report balance sheet. FY2025 from FY2026 Annual Report parent-entity note (total assets 21,708; liabilities 2,478; current liabilities 530). FY2022 total assets from Barchart (aggregator; reported in thousands — figure consistent with AUD filings), FY2022 cash and financial assets from FY2023 opening balances, FY2022 equity from the FY2024 statement of changes in equity; FY2022 liabilities and NTA per share derived. FY2026 total assets derived by the analyst as the sum of disclosed asset lines (cash 697 + receivables 71 + financial assets 20,473 + DTA 20); FY2026 total liabilities derived as total assets less equity — both are approximations, the full FY2026 balance sheet table was not extractable. FY2026 NTA per share is as reported (9.46c).
Cash flow (A$000)
Sources: FY2024 and FY2026 Annual Reports, statements of cash flows. Because the company is an investment entity, purchases and sales of investments are classified in operating cash flow, which makes OCF and FCF reflect portfolio rotation rather than "earnings quality". A more meaningful measure is net cash cost of running the vehicle (payments to employees and suppliers less dividends and interest received): FY2023 about -1.02m; FY2024 about -0.95m; FY2025 about -0.37m; FY2026 about -0.41m.
Ratios
Analyst calculations from the tables above. Price / NTA uses the 30 June closing share prices reported in the remuneration-report TSR tables (FY2022 0.064; FY2023 0.042; FY2024 0.046; FY2025 0.046; FY2026 0.054) divided by reported or derived NTA per share.
Commentary on trends, inflections and drivers
FY2020–FY2022: value destruction. The cumulative net loss over FY2020–FY2022 was about A$60m, driven by the collapse of Canadian cannabis valuations after the 2018 legalisation boom. The FY2021 Annual Report notes the portfolio had a significant unlisted bias (listed assets were only 27% of NAV), and several unlisted investees deferred IPO plans, leaving MMJ unable to realise value while its listed benchmark rallied on IPO and merger activity. Total assets fell from about A$95.7m (FY2019, aggregator) to A$26.4m by FY2022.
FY2023: the bottom and the reset. A further A$4.0m loss (dominated by A$2.8m of unrealised write-downs) took NTA per share to 9.18c. The board responded decisively: it tendered the management mandate, ended the Parallax relationship, renewed the board with value-investing and governance expertise (Sauer, Prescott), and executed a A$1.04m unmarketable-parcel buyback that cancelled 19.6m shares and reduced registry costs.
FY2024: transition year. Net result was a small loss (A$0.13m) as gains on Delivra (+A$1.5m), ETG (+A$0.6m) and Weed Me (+A$0.4m) were almost entirely offset by the Medio Labs write-off (-A$1.96m). Operating expenses fell 30% to A$1.10m. Crucially, cash was deployed: payments for investments of A$5.0m took cash from A$3.7m to A$0.2m and lifted listed holdings from A$0.8m to A$6.8m.
FY2025: liquidation and redeployment. The ETG sale (A$3.8m), the Delivra sale (about C$1.1m) and the Sequoya and Valo realisations converted almost all residual illiquids to cash, which was recycled into ASX listings (A$14.0m of purchases and A$14.8m of disposals, indicating active rotation). The company recorded its first profit under the new manager (A$0.24m), helped by a A$0.2m tax benefit.
FY2026: two halves. NTA rose strongly to 10.89c in the December half (H1 revenue up 356% and profit up 460% year on year, per InvestSMART's summary of the half-year report), then gave back much of the gain in the March quarter, which the manager attributes to a global sell-off in software stocks it calls the "SaaSpocalypse". Full-year profit was A$0.19m. The listed book gained A$2.49m (about 22.9% gross on opening listed capital, per the manager), but Weed Me was written down A$1.80m, from A$8.86m to A$6.98m, despite the investee reporting record sales and paying a dividend. NTA per share rose to 9.46c, aided by buybacks.
Cost discipline is the clearest positive trend. Operating expenses fell from A$1.57m (FY2023) to A$0.84m (FY2026), a 46% reduction, consistent with the board's FY2024 forecast of non-management-fee costs falling to around A$0.7m. CFO base salary was cut from A$225,000 to A$170,000.
The unresolved issue is scale. Even after cuts, the expense ratio of about 4.3% of net assets is several multiples of typical larger LICs, and management itself describes operating costs as a significant headwind for a company of its size.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Ownership | Status |
|---|---|---|---|
Underwood Capital Limited | Australia | Parent, ASX-listed | Active |
Phytotech Medical (UK) Pty Ltd | United Kingdom | 100% | Provided services to the parent; voluntarily wound up and deregistered 30 Dec 2025 |
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total income (AUD K) | -16,338 | -2,592 | 1,199 | 937 | 684 |
Profit before tax (AUD K) | -17,795 | -4,163 | 95 | 46 | -157 |
Total expenses (AUD K) | 1,457 | 1,571 | 1,104 | 890 | 841 |
Total income YoY growth (%) | n/m | n/m | n/m | -21.9 | -27.0 |
Segment Revenue
| Sleeve | FY2024 gain/(loss) AUD K | FY2026 gain/(loss) AUD K | FY2026 book value AUD K |
|---|---|---|---|
Weed Me Inc. (legacy, unlisted, Canada) | 361 | -1,801 | 6,982 |
Delivra Health Brands (legacy, listed, Canada) | 1,502 | 0 | 0 |
Emerging Therapeutics Group (legacy, unlisted, Australia) | 601 | 0 | 0 |
Medio Labs (legacy, unlisted) | -1,959 | 0 | 0 |
Listed ASX securities (HD-managed) | — | 2,488 | 13,104 |
“—” = not publicly disclosed.
Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total income ("revenue") AUD K | -16,338 | -2,592 | 1,199 | 937 | 684 |
Interest and dividend income AUD K | — | 187 | 206 | 540 | 427 |
Net unrealised gains/(losses) AUD K | — | -2,764 | 762 | 1,529 | -698 |
Realised gains/(losses) AUD K | — | -144 | -29 | -1,216 | 955 |
Operating expenses AUD K | 1,457 | 1,571 | 1,104 | 890 | 841 |
Gross profit AUD K (equals total income; no COGS) | -16,338 | -2,592 | 1,199 | 937 | 684 |
Operating income / EBITDA proxy AUD K (equals PBT) | -17,795 | -4,163 | 95 | 46 | -157 |
Profit before tax AUD K | -17,795 | -4,163 | 95 | 46 | -157 |
Income tax (expense)/benefit AUD K | 1,863 | 179 | -226 | 198 | 351 |
Net profit after tax AUD K | -15,932 | -3,984 | -131 | 243 | 193 |
Basic EPS (cents) | -6.93 | -1.74 | -0.06 | 0.12 | 0.09 |
Diluted EPS (cents) | -6.93 | -1.74 | -0.06 | 0.12 | 0.09 |
Dividends per share (cents) | 0 | 0 | 0 | 0 | 0 |
Financial Analysis
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Administration expenses AUD K | 673 | 494 | 333 | 283 |
Asset management expenses AUD K | 189 | 175 | 211 | 249 |
Employee and director expenses AUD K | 654 | 434 | 348 | 310 |
Share-based payments AUD K | 55 | 0 | 0 | 0 |
Total expenses AUD K | 1,571 | 1,104 | 890 | 841 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net margin on total income (%) | n/m | n/m | -10.9 | 25.9 | 28.2 |
PBT margin on total income (%) | n/m | n/m | 7.9 | 4.9 | -23.0 |
Expense ratio, opex / closing net assets (%) | 6.0 | 8.1 | 5.7 | 4.6 | 4.3 |
Total income CAGR FY2022–FY2026 | n/m | n/m | n/m | n/m | n/m |
Share Count (millions) and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets AUD K | 26,351 | 21,964 | 21,896 | 21,708 | 21,261 |
Cash and cash equivalents AUD K | 6,319 | 3,715 | 189 | 534 | 697 |
Financial assets at FVTPL AUD K | 19,195 | 17,478 | 21,543 | 20,733 | 20,473 |
of which listed AUD K | — | 787 | 6,778 | 11,870 | 13,491 |
of which unlisted (equity + debt) AUD K | — | 16,690 | 14,765 | 8,863 | 6,982 |
Total debt (short + long) AUD K | 0 | 0 | 0 | 0 | 0 |
Net debt AUD K (negative = net cash) | -6,319 | -3,715 | -189 | -534 | -697 |
Deferred tax liability AUD K | — | 2,329 | 2,520 | 1,949 | 1,753 |
Total liabilities AUD K | 2,001 | 2,584 | 2,681 | 2,478 | 1,912 |
Total equity / net assets AUD K | 24,350 | 19,380 | 19,215 | 19,230 | 19,349 |
Goodwill and intangibles AUD K | 0 | 0 | 0 | 0 | 0 |
Working capital AUD K (current assets less current liabilities) | — | 21,629 | 21,660 | 21,079 | — |
Shares on issue (millions) | 229.95 | 210.31 | 210.31 | 205.74 | 204.33 |
NTA per share, post-tax (cents) | 10.59 | 9.18 | 9.10 | 9.30 | 9.46 |
Financial Analysis (FY2022–FY2026)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow AUD K (includes investment purchases/sales) | — | -1,528 | -3,489 | 574 | 236 |
Payments for financial assets AUD K | — | -1,234 | -5,026 | -13,958 | -4,785 |
Proceeds from disposals AUD K | — | 35 | 1,597 | 14,819 | 5,155 |
Payments to employees and suppliers AUD K | — | -1,347 | -1,168 | -911 | -832 |
Dividends and interest received AUD K | — | 329 | 222 | 540 | 427 |
Capex AUD K | 0 | 0 | 0 | 0 | 0 |
Free cash flow AUD K (equals OCF; no capex) | — | -1,528 | -3,489 | 574 | 236 |
Dividends paid AUD K | 0 | 0 | 0 | 0 | 0 |
Share buybacks AUD K | — | 1,040 | 35 | 228 | 73 |
Net change in cash AUD K | — | -2,568 | -3,524 | 346 | 163 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity (%) | -65.4 | -20.6 | -0.7 | 1.3 | 1.0 |
ROA on closing total assets (%) | -60.5 | -18.1 | -0.6 | 1.1 | 0.9 |
ROIC (%) (equals ROE; no debt) | -65.4 | -20.6 | -0.7 | 1.3 | 1.0 |
Current ratio (x) | — | 85.8 | 135.5 | 40.8 | — |
Debt / equity (x) | 0 | 0 | 0 | 0 | 0 |
Net debt / EBITDA (x) | n/m | n/m | n/m | n/m | n/m |
Interest coverage (x) | n/m | n/m | n/m | n/m | n/m |
Asset turnover, total income / total assets (x) | -0.62 | -0.12 | 0.05 | 0.04 | 0.03 |
Cash conversion cycle (days) | n/m | n/m | n/m | n/m | n/m |
Price / NTA at 30 June (x) | 0.60 | 0.46 | 0.51 | 0.49 | 0.57 |
Geographic Revenue
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Canada (named holdings) AUD K | 10,878 | 11,549 | 8,863 | 6,982 |
Australia / ASX (named holdings) AUD K | 3,982 | 3,993 | 11,870 | 13,491 |
Finland (Valo Therapeutics) AUD K | 500 | 600 | 0 | 0 |
Mixed or unallocated (other listed/unlisted, Medio Labs) AUD K | 2,117 | 5,401 | 0 | 0 |
Total financial assets AUD K | 17,477 | 21,543 | 20,733 | 20,473 |
Revenue by Region (%)
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Canada (%) | 62.2 | 53.6 | 42.7 | 34.1 |
Australia (%) | 22.8 | 18.5 | 57.3 | 65.9 |
Finland (%) | 2.9 | 2.8 | 0 | 0 |
Mixed (%) | 12.1 | 25.1 | 0 | 0 |
Share Price and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.064 | 0.042 | 0.046 | 0.046 | 0.054 |
NTA per share (cents) | 10.59 | 9.18 | 9.10 | 9.30 | 9.46 |
Discount to NTA (%) | 39.6 | 54.2 | 49.5 | 50.5 | 42.9 |
Shares on issue (millions) | 229.95 | 210.31 | 210.31 | 205.74 | 204.33 |
Market cap at 30 June (AUD Mn) | 14.7 | 8.8 | 9.7 | 9.5 | 11.0 |
Share Price History
| Period | Start price | End price | Return |
|---|---|---|---|
1 year (Jun 2025 – Jun 2026) | 0.046 | 0.054 | +17.4% |
3 years (Jun 2023 – Jun 2026) | 0.042 | 0.054 | +28.6% |
5 years (Jun 2021 – Jun 2026) | 0.077 | 0.054 | -29.9% |
7 years (Jun 2019 – Jun 2026) | 0.250 | 0.054 | -78.4% |
Valuation Multiples
| Multiple | Value (FY2026) | Comment |
|---|---|---|
P/E | about 60x (5.4c / 0.09c) | Not meaningful for an LIC |
Price / NTA (post-tax) | about 0.57x | Primary valuation metric |
Price / pre-tax NTA | lower (pre-tax NTA exceeds post-tax by the DTL of about A$1.75m, about 0.86c per share) | Analyst estimate |
Price / liquid assets per share | about 0.78x (5.4c vs about 6.9c of cash plus listed securities, pre-tax) | Market ascribes negative value to Weed Me and costs |
P/B | about 0.57x | Equals P/NTA (no intangibles) |
Capital Markets
| Item | Detail |
|---|---|
Dividend history | No dividends paid, recommended or declared in FY2022–FY2026 |
Dividend policy | Not formally published; FY2024 report notes available funds are affected by income tax and "HGV's dividend policy" |
Franking balance | Nil at 30 Jun 2026 (A$82,319 at 30 Jun 2025; A$28,709 at 30 Jun 2024) |
Buybacks | Unmarketable parcel Jun 2023 (19.64m shares, A$1.04m); FY2025 unmarketable parcel (4.57m shares, A$0.23m); on-market program Sep 2024 – Oct 2025 (up to 21.03m shares; about 0.4m bought in FY2026 for A$0.02m); on-market program from 10 Apr 2026 (up to about 20.53m shares; 1.80m bought by 30 Jun 2026 at A$0.0525 average); extension to 27 Oct 2026 reported |
Cumulative reduction in share count | From 229.95m (Jun 2022) to 203.53m (Jul 2026), about -11.5%; the manager cites about 4% repurchased since its appointment (excluding the June 2023 parcel buyback) |
Analyst Conclusions
Management guidance
No quantitative guidance is provided. Management states the portfolio's performance is materially dependent on global equity markets, that the buyback is expected to remain active while shares trade at a significant discount to NTA, and that Weed Me monetisation is being actively pursued.
Consensus
None. No sell-side coverage was identified.
Bull case
-
Sum-of-the-parts underpinning: at about 5.4c, the share price is below the roughly 6.9c per share of cash and listed securities alone. Investors receive the Weed Me stake (book about 3.4c per share pre-tax), the tax assets and the manager's process for free. Even a sale of Weed Me at a 30% discount to book would release roughly 2.4c per share of cash.
-
Proven manager in an aligned structure: a gross return of about 22.9% on listed capital in FY2026 and over 10% annualised ex-Weed Me NTA growth since July 2023, with the manager as the largest shareholder and the Chair buying.
-
Self-help capital management: buybacks at about a 45% discount to NTA are mechanically accretive; continued cost reductions and potential Weed Me dividends could make the vehicle cash-neutral on running costs.
Bear case
-
Structural sub-scale trap: about A$0.84m of costs on A$19m means roughly 4.3% annual drag; buybacks shrink the asset base and worsen the ratio. Without growth or a corporate event, the discount may never close.
-
Weed Me is hard to sell: an unlisted, CAD-denominated stake in a sector trading at about 0.9x revenue; its value fell 21% in FY2026 despite record sales. Forced or delayed sale could crystallise losses.
-
Tech-skewed concentration risk: a handful of ASX software and services names in a world of AI disruption uncertainty; the March 2026 quarter showed the portfolio can give back half-year gains rapidly.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Timing | What to watch |
|---|---|---|
| 2026 AGM | 26 Nov 2026 | Auditor ratification (Stannards); any shareholder pressure on discount; board renewal |
| Weed Me transaction | Any time | Sale price relative to the A$6.98m book |
| Monthly NTA releases | Monthly | Trajectory versus 9.46c; recovery of software holdings |
| Buyback execution and renewal | Program to Oct 2026 and beyond | Volume repurchased; renewal at up to 10% |
| Half-year results to 31 Dec 2026 | Late Feb 2027 | Expense ratio; tax position; Weed Me valuation multiple |
| Substantial holder notices | Ongoing | Accumulation by HD Capital, Benjamin Graham, or activist LIC investors |
| Dividend policy | FY2027 | Any reinstatement once franking credits are generated |
| IMA horizon | 30 Jun 2028 | Early signals on renewal or restructuring |
Concluding analyst verdict
Underwood Capital is no longer the company described by the identifiers supplied for this research. The cannabis investment vehicle known as MMJ Group Holdings, and later Hygrovest, is effectively finished: of the roughly A$74 million once deployed into North American cannabis, only the Weed Me stake remains, carried at A$7.0 million. In its place sits a small, debt-free, value-oriented listed investment company run by an aligned external manager whose own record since July 2023 is credible — a cost base nearly halved, legacy assets realised at or above carrying value, and a listed book that returned about 23% gross in FY2026.
The investment debate, however, is not about the manager's stock-picking. It is about structure. At about A$19 million of net assets, the vehicle's fixed costs consume more than four percent of capital each year, the stock is illiquid, there is no dividend, and the market has refused to close a 40–55% discount to NTA for four consecutive years despite a dramatic improvement in portfolio quality. The share price sits below the value of liquid assets alone, which is an unusually strong margin of safety, but margins of safety only pay out when something forces the gap to close.
The two most plausible forcing events are a sale of the Weed Me stake, which management is now openly soliciting, and a more aggressive capital-return or corporate solution for the vehicle itself, for which there is no announcement. Buybacks help at the margin but are constrained by liquidity and slowly worsen the cost ratio.
Our assessment: asymmetric but catalyst-dependent. Downside appears limited by liquid asset backing and a clean balance sheet; upside requires either a Weed Me realisation near book or a structural resolution of sub-scale. Absent either within the next 12–24 months, the most likely outcome is continued modest NTA growth with a persistent discount. Monitor the 26 November 2026 AGM and any Weed Me announcement closely.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Shares held |
|---|---|---|---|---|---|
Warwick Sauer | Independent Non-Executive Chair | NED 20 Mar 2023; Chair 1 Aug 2023 | Corporate lawyer with 25 years' experience in commercial law, capital markets, M&A and litigation; 14 years at JLL including 7 years as General Counsel for JLL's A$4bn APAC business; director of a private investment company (previously described as investing in deep-value and "net/net" stocks); former director of BSA Limited | B.Com (financial accounting) and LLB, University of Queensland | 3,223,787 (up from 1,242,010; bought 1,981,777 in FY2026) |
David Prescott | Independent Non-Executive Director | 20 Mar 2023 | Founder and Managing Director of Lanyon Asset Management (value-oriented equities manager); 20+ years in investing and analysis in Australia and the UK; former Head of Equities at CP2 (formerly Capital Partners); former director of Lanyon Investment Company and BSA Limited | Economics, University of Adelaide; Grad Dip Applied Finance and Investment (FINSIA); CFA charterholder | Nil |
Jason Byrne | Independent Non-Executive Director | 1 Aug 2023 | 30+ years building businesses in wagering technology, digital place-based advertising, e-commerce, legal technology, apparel logistics, procurement technology and offshore development; director of Motio Limited (ASX: MXO) | — | Nil |
“—” = not publicly disclosed.
Executive Leadership Team
| Name | Role | Tenure | Background | Base salary |
|---|---|---|---|---|
James (Jim) Hallam | Chief Financial Officer and Company Secretary (sole employee) | CFO since 3 Apr 2018; Company Secretary since 22 Jun 2018 | About 30 years in investment management with alternative asset managers including Hastings Funds Management and Annuity Australia; former responsible manager, investment manager and CFO roles | A$170,000 (reduced from A$225,000); 6-month termination benefit and notice period |
Executive Leadership Team (Annual)
| Name | FY2025 total | FY2026 total | FY2026 composition |
|---|---|---|---|
Warwick Sauer (Chair) | 58,133 | 54,806 | Fees 48,934 + super 5,872 |
Jason Byrne | 41,933 | 38,600 | Fees |
David Prescott | 41,933 | 38,600 | Fees |
Jim Hallam (CFO/CoSec) | 205,445 | 178,490 | Salary 154,034 + super 30,000 + leave movement (5,544) |
Total KMP | 347,444 | 310,496 | 100% fixed; no STI, LTI or equity grants |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
20 Mar 2023 | Sauer and Prescott join the board | Value-investing and legal expertise added during the manager tender |
1 Aug 2023 | Peter Wall (Chair) and Doug Halley retire; Jason Byrne appointed; Sauer becomes Chair | Board reduced to three to cut costs; full break from the cannabis-era board |
FY2023 | Winton Willesee and Michael Curtis depart (received FY2023 fees) | Earlier board refresh |
1 Dec 2023 | Board and CFO voluntarily cut pay 10% | Cost program |
Mar 2024 / Mar 2026 | Auditor changes (BDO to Connect National Audit; then to Stannards) | Cost-driven audit tenders |
Major Shareholders
| Rank | Holder | Shares | % |
|---|---|---|---|
| 1 | J P Morgan Nominees Australia Pty Limited | 31,995,378 | 15.72 |
| 2 | BNP Paribas Nominees Pty Ltd (Clearstream) | 12,074,704 | 5.93 |
| 3 | Mr Benjamin Youngman Graham (Graham Family A/C) | 11,200,000 | 5.50 |
| 4 | Perpetual Corporate Trust Ltd (Affluence LIC Fund) | 7,694,213 | 3.78 |
| 5 | Mr George Chien-Hsun Lu | 6,817,707 | 3.35 |
| 6 | Mr Peter C Wall & Mrs Tanya-Lee Wall (Wall Family Super A/C) | 4,500,000 | 2.21 |
| 7 | Maxlek Pty Ltd (Jims and Joels Super A/C) | 4,425,000 | 2.17 |
| 8 | Jaindi Investments Pty Ltd | 3,850,000 | 1.89 |
| 9 | BNP Paribas Nominees Pty Ltd (IB AU Noms Retail Client) | 3,474,929 | 1.71 |
| 10 | Mrs Lily Mah (MJ A/C) | 3,298,240 | 1.62 |
Competitive Landscape
Key Competitors
| Peer (ASX code) | Category | Relative positioning vs UWC |
|---|---|---|
WAM Microcap (WMI) | Micro-cap LIC | Far larger, established dividend payer, trades nearer NTA |
NAOS Small Cap Opportunities (NSC) | Concentrated small-cap LIC | Similar concentrated style; larger scale |
Thorney Opportunities (TOP) | Activist / special situations | Closest in style (activist, discount to NTA) |
Sandon Capital Investments (SNC) | Activist LIC | Activist value; dividend-paying |
Glennon Small Companies (GC1) | Small-cap LIC | Comparable small scale; discount issues |
Acorn Capital Investment Fund (ACQ) | Listed and unlisted micro-cap | Mixed listed/unlisted exposure, similar to UWC's legacy profile |
Spheria Emerging Companies (SEC) | Small/micro-cap value | Larger; value style |
Ophir High Conviction Fund (OPH) | Concentrated growth | Different style (growth) |
Bailador Technology Investments (BTI) | Unlisted technology investor | Overlapping tech exposure; private-company focus |
Affluence LIC Fund (unlisted; holder of UWC) | Fund-of-LICs | A shareholder that buys discounted LICs — a potential catalyst rather than a competitor |
Competitor Detail
| Metric | UWC FY2026 |
|---|---|
Net assets | A$19.3m |
NTA per share growth (FY2026) | +1.7% |
Expense ratio | about 4.3% of net assets |
Price / NTA | about 0.57x |
Dividend yield | 0% |
Recent Developments
Monthly NTA announcements are lodged routinely; only those with confirmed figures are listed.
There were no guidance revisions, litigation, regulatory actions, layoffs or contract wins in the period (none disclosed).



